Moxalactam, Ro 13-9904, cefotaxime, cefoperazone, older cephalosporins, and four aminoglycosides were tested in vitro against 432 strains of gram-negative bacteria isolated from pediatric patients. The new drugs were uniformly active against coliform bacilli obtained from patients with meningitis and against aminoglycoside-resistant coliform bacilli. forming units of inoculum diluted from overnight Mueller-Hinton broth seed cultures after 16 h of incubation at 35°C. A Steers-Foltz replicating device was used. In all tests, an inoculum control was performed with each strain, and the actual range of inocula was from 5 x 104 to 1 x 10' colony-forming units. Haemophilus strains were tested with 1% supplement C (Difco Laboratories) added to the media. Gonococci were tested on proteose no. 3 agar (Difco) with 1% hemoglobin (Difco) and 1% IsoVitaleX (BBL Microbiology Systems) and incubated in a candle extinction jar. Freshly prepared antibiotic standards were incorporated into the agar. With cefotaxime, cefoperazone, moxalactam, and Ro 13-9904, twofold dilutions from 32 ,ug/ml were used; with other antibiotics, the twofold dilutions were from 20 ,ug/ml. Cefoperazone was tested only against the coliform meningitis strains. The MIC was determined as the lowest concentration causing no growth or fewer than 10 discrete colonies, which represented more than 99% inhibition. Resistance was defined as an MIC of more than 8 or 10 lOg/ml.
philus influenzae type b, and nosocomial infections caused by bacilli that are multiply resistant to aminoglycoside antibiotics. Accordingly, we have tested the above-mentioned drugs, cefoxitin, cefamandole, cefuroxime, ampicillin, and four aminoglycosides (gentamicin, kanamycin, amikacin, and netilmicin) against a variety ofgram-negative bacilli isolated from pediatric patients. The meningitis strains of coliform bacilli were from patients enrolled in the Neonatal Meningitis Cooperative Study (3) . and the multiply aminoglycoside-resistant coliforms were mainly strains sent to our laboratory from many institutions in North and South America. The Pseudomonas strains were 10' colony-forming units. Haemophilus strains were tested with 1% supplement C (Difco Laboratories) added to the media. Gonococci were tested on proteose no. 3 agar (Difco) with 1% hemoglobin (Difco) and 1% IsoVitaleX (BBL Microbiology Systems) and incubated in a candle extinction jar. Freshly prepared antibiotic standards were incorporated into the agar. With cefotaxime, cefoperazone, moxalactam, and Ro 13-9904, twofold dilutions from 32 ,ug/ml were used; with other antibiotics, the twofold dilutions were from 20 ,ug/ml. Cefoperazone was tested only against the coliform meningitis strains. The MIC was determined as the lowest concentration causing no growth or fewer than 10 discrete colonies, which represented more than 99% inhibition. Resistance was defined as an MIC of more than 8 or 10 lOg/ml.
Modal MICs are shown in Table 1 , and MICs for 90% of the strains are shown in Table 2 . Salmonella spp., Shigella spp. and 18-lactamase-negative gonococci were uniformly susceptible to low concentrations of moxalactam, Ro 13-9904, and cefotaxime. One Salmonella strain was resistant to cefoxitin, three strains were resistant to cefamandole, four strains were resistant to ampicillin and cefuroxime, and two strains were resistant to kanamycin. Ampicillinresistant and -susceptible Shigella strains were comparably inhibited by cefoxitin, cefuroxime, and the aminoglycosides. However, with cefamandole, ampicillin-susceptible Shigella spp. were inhibited by 1 ,ug/ml or less, but 21 ampicillin-resistant Shigella spp. required from 2 to 8 ,g/ml for inhibition, and two strains were resistant.
Most Pseudomonas aeruginosa strains, including the 14 strains resistant to carbenicillin and the aminoglycosides, were inhibited by 8 or 16 ,Lg of moxalactam, Ro 13-9904, or cefotaxime per ml, but 11, 8, and 9 strains, respectively, required 32 yg/ml for inhibition. One strain of Pseudomonas cepacia and one of Pseudomonas maltophilia were susceptible to the three drugs.
Susceptibilities of the coliform bacteria from infants with meningitis are shown in Fig. 1 Of the multiply resistant coliform bacilli, 73% were resistant to gentamicin, 97% were resistant to kanamycin, 64% were resistant to netilmicin, and only 4% were resistant to amikacin. The number of resistant strains included 23 Klebsiella spp., 17 E. coli, 9 Enterobacter spp., 7 Serratia spp., and 1 Salmonella sp. All were inhibited by less than 1 ug of moxalactam, Ro 13-9904, and cefotaxime per ml. Cefamandole was somewhat less active than cefuroxime or cefoxitin (Fig. 2) . With the exception of ampicillin, f8-lactamasepositive and -negative H. influenzae type b were comparably inhibited by each drug, but the three new drugs were most active, and cefoxitin was somewhat less active than cefuroxime or cefamandole (Fig. 3) .
In summary, the new cephalosporin derivatives were uniformly more active against coliform bacilli, Haemophilus spp., and gonococci than cefuroxime, cefamandole, cefoxitin, and the aminoglycosides. Their activity against P. aeruginosa was considerably less, but they were active against carbenicillin-and aminoglycosideresistant strains. All coliform bacilli from patients with meningitis and all aminoglycosideresistant coliform bacilli were susceptible to extremely low concentrations of these investigational drugs. The order of activity was as follows: Ro 13-9904 > cefotaxime > moxalactam > cefoperazone. However, these differences would probably be of little clinical importance, in view of the great potency of all of them. With aminoglycoside therapy, an average of 3.5 days. is required to sterilize the cerebrospinal fluid in infants with coliform meningitis (3). The possibility that the greatly increased in vitro activity of these new agents will result in more rapid eradication of bacteria is supported by experiments with moxalactam in the infant rat (2) and rabbit (4) 
